Not surprisingly, therapies that induced epigenetic-based differentiation of AML into homogeneous lineage states, such as IDH1, IDH2 and menin inhibitors90–93 have demonstrated promising therapeutic options in AML. Here, IDH1 is linked to acute myeloid leukemia.